STAAR Surgical insider Form 4 shows 15K-share equity award to director

Rhea-AI Filing Summary

STAAR Surgical Co. (STAA) – Form 4 insider filing

On 18 June 2025, non-employee director Dr. Elizabeth Yeu received her annual board equity package:

• Restricted Stock Units (RSUs): 5,341 – each RSU converts to one common share upon vesting.
• Stock Options: 9,708 – exercise price $16.85, expire 17 June 2035.

The RSUs and options both vest in full on the earlier of 18 June 2026 or the company’s 2026 Annual Meeting of Shareholders. All securities are held directly and no open-market purchases or sales were reported. The grant represents potential issuance of up to 15,049 shares and arises from the standard non-employee director compensation program for the 2025-2026 term. No financial results, cash transactions, or changes in ownership percentages were disclosed.

Positive

• Alignment of interests: Granting RSUs and at-market priced options to a non-employee director ties compensation directly to future share performance.

Negative

• Potential dilution: The issuance of 15,049 shares upon vesting/exercise adds to share count, albeit at a small scale.

Insights

Financial Analyst

TL;DR: Routine director equity grant; immaterial dilution; neutral signal for STAA shares.

This Form 4 discloses the company’s annual compensation to a non-employee director rather than an open-market trade. The package (≈15 K potential shares) is modest relative to STAAR’s share count and therefore unlikely to move valuation or liquidity metrics. At $16.85, the 10-year options align Dr. Yeu’s incentives with long-term shareholder value creation, but do not convey management sentiment about near-term price direction. Because there are no purchases, sales, or unusual terms, the filing is best viewed as routine governance housekeeping with negligible market impact.

Corporate Governance Expert

TL;DR: Standard board-level equity award; supports alignment, carries minimal governance risk.

The disclosure confirms STAAR’s adherence to its established non-employee director equity plan. Full one-year cliff vesting and a 10-year option term are conventional and encourage medium-to-long-term oversight. No 10b5-1 plan was indicated, implying flexibility for future trading once vested. From a governance lens, the award size does not appear excessive and there are no red flags such as accelerated vesting or repricing. Consequently, the event is considered neutral in impact, merely documenting compliance with Section 16 reporting obligations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Elizabeth Yeu

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	06/18/2025		A		5,341		(2)	(2)	Common Stock	5,341	$0	5,341	D
Common Stock Options	$16.85	06/18/2025		A		9,708		06/18/2026(2)	06/17/2035	Common Stock	9,708	$0	9,708	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting.

2. These equity awards vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.

Remarks:

This Form 4 reflects the equity awards granted to the Reporting Person on June 18, 2025, pursuant to the Corporation's annual non-employee director equity compensation program for the 2025-2026 term.

	/s/ Nathaniel Sisitsky as attorney-in-fact for Dr. Elizabeth Yeu	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did STAAR Surgical (STAA) disclose in the 20 June 2025 Form 4?

The filing reports a routine equity grant to director Dr. Elizabeth Yeu consisting of 5,341 RSUs and 9,708 stock options.

How many RSUs were granted to Dr. Elizabeth Yeu?

5,341 Restricted Stock Units were granted on 18 June 2025.

What is the exercise price and expiration date of the new options?

The options have a $16.85 exercise price and expire on 17 June 2035.

When do the RSUs and options vest?

Both awards vest fully on the earlier of 18 June 2026 or STAAR Surgical’s 2026 Annual Meeting of Shareholders.

Did the Form 4 report any stock sales or open-market purchases?

No. The filing only reflects new grants; no shares were bought or sold.